Validation of a limited sampling model to determine etoposide area under the curve

Pharmacotherapy

Volumn 17, Issue 5 I, 1997, Pages 887-890

  Lum, Bert L ^a,b,c,d   Lane, Kevin J ^b   Synold, Timothy W ^e   Goram, Adrian ^f   Charnick, Steven B ^g   Sikic, Branimir I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MONITORING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; SAMPLING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ETOPOSIDE; HUMANS; INFUSIONS, INTRAVENOUS; MODELS, BIOLOGICAL; NEOPLASMS; SAMPLING STUDIES;

EID: 0030825065     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE. Etoposide (VP-16-213) current status of an active anticancer drug. N Engl J Med 1985;312:692-700.
2. 14C-etoposide in man [abstr]. Proc Am Soc Clin Oncol 1995;14168.
3. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 1987;47:1952-6.
4. Newman EM, Doroshow JH, Forman SJ, Blume KG. Pharmacokinetics of high-dose etoposide. Clin Pharmacol Ther 1988;43:561-4.
5. Ratain MJ, Mick R, Schilsky RL, et al. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 1991;9:1480-6.
6. Stewart CF, Arbuck SG, Fleming RA, et al. Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 1991;46:385-93.
7. Miller AA, Tolley EA, Niell HB, et al. Pharmacodynamics of three day infusions of etoposide in patients with extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 1992;31:161-6
8. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-42.
9. Lum BL, Fisher GA, Hausdorf J, et al. The effect of oral SDZ PSC 833 on the pharmacokinetics of etoposide during a phase I trial to modulate multidrug resistance [abstr]. Anticancer Drugs 1994;5(suppl 1):44.
10. Joel SP, Heap L, Clarke PI, et al. A limited sampling strategy for the calculation of etoposide pharmacokinetics [abstr]. Proc Am Soc Clin Oncol 1990;9:260.
11. Harvey VJ, Joel SP. High-performance liquid chromatography of etoposide in plasma and urine. J Chromatogr 1985;339: 419-23
12. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9: 503-12.
13. Stromgren AS, Sorensen BT, Jakobsen P, et al. A limited sampling method for estimation of the etoposide area under the curve. Cancer Chemother Pharmacol 1993;32:226-30
14. Ratain MJ, Schilsky RL, Choi KE, et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 1989;45:226-33.